RVA - Reabsorbable coronary stent

http://imagesignal.comsec.com.au/asxdata/20101221/pdf/01135111.pdf

http://imagesignal.comsec.com.au/asxdata/20110523/pdf/01182695.pdf

http://www.theaustralian.com.au/business/hearts-aflutter-as-coronary-revolution-looms/story-e6frg8zx-1226062242178

After reading the article in The Australian, I thought this is worth a gamble. If everything that is said about this company is true, then if there is no competitor, this has got to be godsend to mankind. Especially those who eat like pigs and there are plenty of those in wealthy countries.

But nothing is straight forward. Research and innovative medical company has a long way to go before success. There are competitors, there are regulatory hurdles and unexpected complications that will turn a promising company into history. All biotechs are very high risk. You really only make money because a big pharmaceutical company takes it over. This company already has a working relationship with Boston Scientific and Medtronics. They had invested in the development of the product.

Today, I manage to buy at the original issue price in Dec 2010. So while I had to pay commission to CommSec, it is actually cheaper than what the original investors had to pay for. After I bought (in fact, I was the first cab off the rank this AM!), the share price started to move up. But by close of trade, the price has gone up by only 0.5c. This kind of stock is bought for the medium term.